The Effect of Flow on Lysis of Plasma Clots in a Plasma Environment

Summary

Fibrinolysis initially generates channels in an occluding thombus which results in blood flow through the thrombus. Since the impact of flow along the surface of a thrombus on thrombolysis has not been investigated in detail, we studied in vitro how such a flow affects lysis. Compacted and noncompacted plasma clots were used as model thrombi. With compacted clots, fibrin-specific lysis induced by alteplase in the outer plasma was accelerated about 2-fold by strong flow (arterial shear rate). Non-fibrin-specific lysis induced either by a high concentration of alteplase or by streptokinase was slow, was accompanied by rapid depletion of plasminogen in the outer plasma, and was only slightly accelerated by flow. With noncompacted clots, similar acceleration factors were documented, when mild flow (venous shear rate) was applied. Strong flow further accelerated fibrin-specific lysis, up to 10-fold as compared to lysis without flow, but paradoxically retarded non-fibrin-specific lysis. The data suggest that flow accelerates lysis by enhancing transport of plasminogen from the outer plasma to the surface of the clot. Both opposite effects of the strong flow were mediated by forceful intrusion of the outer plasma into the noncompacted clot due to flow irregularities. In the case of non-fibrin-specific lysis this resulted in the replacement of the plasminogen-containing milieu by plasminogen-depleted outer plasma in certain areas of the clot turning them into virtually unlysable fragments. This flow-enforced “plasminogen steal” may contribute to the relatively high percentage of incomplete thrombolysis (TIMI-2 grade flow) documented in a number of trials for non-fibrin-specific thrombolytic agents. In the case of fibrin-specific lysis, the effect of flow on the speed of fibrinolysis is always beneficial.

Keywords

Fibrinolysis - thrombolysis - plasminogen - flow - fibrin-specificity

• References

• 1 Blinc A, Planinsic G, Keber D, Jarh O, Lahainar G, Zidansek A, Demsar F. Dependence of blood clot lysis on the mode of transport of urokinase into the clot – a magnetic resonance imaging study in vitro. Thromb Haemost 1991; 65: 549-52.
• 2 Diamond SL, Anand S. Inner clot diffusion and permeation during fibrinolysis. Biophys J 1993; 65: 2622-43.
• 3 Blinc A, Kennedy SD, Bryant RG, Marder VJ, Francis CW. Flow through clots determines the rate and pattern of fibrinolysis. Thromb Haemost 1994; 71: 230-5.
• 4 Anand S, Diamond SL. Computer simulation of systemic circulation and clot lysis dynamics during thrombolytic therapy that accounts for inner clot transport and reaction. Circulation 1996; 94: 763-74.
• 5 Anand S, Kudallur V, Pitman EB, Diamond SL. Mechanisms by which thrombolytic therapy results in nonuniform lysis and residual thrombus after reperfusion. Ann Biomed Eng 1997; 25: 964-74.
• 6 Nishino N, Scully MF, Rampling MV, Kakkar VV. Properties of thrombolytic agents in vitro using a perfusion circuit attaining shear stress at physiological levels. Thromb Haemost 1990; 64: 550-5.
• 7 Komorowicz E, Kolev K, Lerant I, Machovich R. Flow-rate-modulated dissolution of fibrin with clot-embedded and circulating proteases. Circ Res 1998; 82: 1102-8.
• 8 Sakharov DV, Rijken DC. Superficial accumulation of plasminogen during plasma clot lysis. Circulation 1995; 92: 1883-90.
• 9 Sakharov DV, Nagelkerke JF, Rijken DC. Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy. J Biol Chem 1996; 271: 2133-8.
• 10 Sabovic M, Lijnen HR, Keber D, Collen D. Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis. Thromb Haemost 1990; 64: 450-4.
• 11 Sakharov DV, Barrett-Bergshoeff M, Hekkenberg RT, Rijken DC. Fibrinspecificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro. Thromb Haemost 1999; 81: 605-12.
• 12 Nishino N, Kakkar VV, Scully MF. Influence of intrinsic and extrinsic plasminogen upon the lysis of thrombi in vitro. Thromb Haemost 1991; 66: 672-7.
• 13 Watahiki Y, Scully MF, Ellis V, Kakkar VV. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator. Thromb Haemost 1989; 61: 502-6.
• 14 Tanswell P, Tebbe U, Neuhaus K, Glasle-Schwarz L, Wojcik J, Seifried E. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol 1992; 19: 1071-5.
• 15 Pislaru SV, van de Werf FG. The current role of thrombolytic therapy in the treatment of acute myocardial infarction. Fibrinolysis & Proteolysis 1999; 13: 78-90.
• 16 Zahger D, Karagounis LA, Cercek B, Anderson JL, Sorensen S, Moreno F, Shah PK. Incomplete recanalization as an important determinant of thrombolysis in myocardial infarction (TIMI) grade 2 flow after thrombolytic therapy for acute myocardial infarction. TEAM investigators. Thrombolytic trial of eminase in myocardial infarction. Am J Cardiol 1995; 76: 749-52.
• 17 Reiner JS, Lundergan CF, Fung A, Coyne K, Cho S, Israel N, Kazmierski Z, Pilcher G, Smith J, Rohrbeck S, Thompson M, Van de Werf F, Ross AM. Evolution of TIMI 2 flow after thrombolysis for acute myocardial infarction. GUSTO-1 angiographic investigators. Circulation 1996; 94: 2441-6.
• 18 Anderson JL, Karagounis LA, Becker LC, Sorensen SG, Menlove RL. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 study. Circulation 1993; 87: 1829-39.
• 19 Bugelski PJ, Kopia GA, Kopaciewicz L, Cadogan AS, Morgan DG. Ultrastructural analysis of thrombolysis by streptokinase and tissue-type plasminogen activator of experimental coronary arterial thrombosis. Fibrinolysis 1989; 03: 137-45.
• 20 Sobel BE, Nachowiak DA, Fry ETA, Bergman SR, Torr SR. Paradoxical attenuation of fibrinolysis attributable to “plasminogen steal” and its implications for coronary thrombolysis. Coron Artery Dis 1990; 01: 111-9.
• 21 Torr SR, Nachowiak DA, Fujii S, Sobel BE. “Plasminogen steal” and clot lysis. J Am Coll Cardiol 1992; 19: 1085-90.
• 22 The GUSTO angiographic investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-22.
• 23 Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 4 trial. J Am Coll Cardiol 1994; 24: 1602-10.
• 24 Barbagelata NA, Granger CB, Oqueli E, Suarez LD, Borruel M, Topol EJ, Califf RM. TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis. Am Heart J 1997; 133: 273-82.